Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Shionogi & Co., Ltd.
  6. News
  7. Summary
    4507   JP3347200002

SHIONOGI & CO., LTD.

(4507)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shionogi : Japan's Shionogi starts Phase II/III clinical trial for new COVID-19 vaccine

10/21/2021 | 03:39am EST

TOKYO, Oct 21 (Reuters) - Japan' Shionogi & Co Ltd said on Wednesday it had started a Phase II/III clinical trial for its COVID-19 vaccine candidate.

The trial for the recombinant protein-based vaccine will take place in Japan and follows a Phase I trial in the country, Shionogi said in a statement. The company will also prepare to conduct multiple trials globally, it said.

Medicines usually have to pass three phases of clinical trials before they can be assessed for approval by regulators.

Separately, Daiichi Sankyo Co said it planned to start a Phase II trial for its COVID-19 vaccine candidate next month.

The Japanese drugmaker is aiming for commercialization of the mRNA-type vaccine, known as DS-5670, in 2022, it said in a statement. (Reporting by Rocky Swift Editing by Jacqueline Wong and Mark Potter)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
DAIICHI SANKYO COMPANY, LIMITED -3.06% 2942 End-of-day quote.-16.78%
SHIONOGI & CO., LTD. -2.67% 8093 End-of-day quote.43.62%
All news about SHIONOGI & CO., LTD.
01:49aVietnam Partners with Japan's Shionogi, Another Firm on Infectious Disease Control
MT
11/24SHIONOGI : Notice Regarding the Signing of a Memorandum of Understanding with Vietnam for ..
PU
11/08Japan stocks end lower as dour earnings hit construction firms
RE
11/03Shionogi's Attributable Profit Drops 25% in Fiscal Q2; Ups FY22 Revenue Target
MT
10/31Shionogi Negotiating With Companies Over Partnership on Covid-19 Pill
DJ
10/312Q Presentation material
PU
10/312Q Financial Results Supplement
PU
10/31Shionogi & Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending Mar..
CI
10/31Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending ..
CI
10/31Shionogi & Co., Ltd. Announces Dividend for the Six Months Ended September 30, 2021, Pa..
CI
More news
Analyst Recommendations on SHIONOGI & CO., LTD.
More recommendations
Financials
Sales 2022 300 B 2 648 M 2 648 M
Net income 2022 104 B 920 M 920 M
Net cash 2022 368 B 3 245 M 3 245 M
P/E ratio 2022 23,3x
Yield 2022 1,37%
Capitalization 2 440 B 21 524 M 21 520 M
EV / Sales 2022 6,90x
EV / Sales 2023 5,57x
Nbr of Employees 5 485
Free-Float 87,9%
Chart SHIONOGI & CO., LTD.
Duration : Period :
Shionogi & Co., Ltd. Technical Analysis Chart | 4507 | JP3347200002 | MarketScreener
Technical analysis trends SHIONOGI & CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 8 093,00 JPY
Average target price 8 080,77 JPY
Spread / Average Target -0,15%
EPS Revisions
Managers and Directors
Isao Teshirogi President & Representative Director
Motozo Shiono Chairman
Teppei Mogi Independent Outside Director
Keiichi Ando Independent Outside Director
Hiroshi Ozaki Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
SHIONOGI & CO., LTD.43.62%21 733
JOHNSON & JOHNSON1.82%421 847
ROCHE HOLDING AG17.17%334 769
PFIZER, INC.38.25%285 639
NOVO NORDISK A/S68.76%247 704
ELI LILLY AND COMPANY55.18%237 527